Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.09), Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.
Enanta Pharmaceuticals Stock Down 3.0%
NASDAQ:ENTA traded down $0.33 during trading hours on Monday, reaching $10.66. The company had a trading volume of 106,587 shares, compared to its average volume of 214,516. Enanta Pharmaceuticals has a twelve month low of $10.05 and a twelve month high of $17.15. The firm has a market cap of $310.53 million, a price-to-earnings ratio of -4.42 and a beta of 0.75. The business’s 50-day simple moving average is $11.95 and its two-hundred day simple moving average is $13.08.
Analysts Set New Price Targets
Several equities research analysts recently commented on ENTA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd. Finally, Wall Street Zen lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, October 11th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.00.
View Our Latest Analysis on Enanta Pharmaceuticals
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.
Read More
- Five stocks we like better than Enanta Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
